Report Summary 1. Industry Investment Rating No industry investment rating is provided in the report. 2. Core View The market is characterized by a structural trend. On January 19, the four major index futures contracts for the current month showed mixed performance. On the trading day, the total trading volume of index futures declined, indicating a decrease in investors' trading enthusiasm. The positions of the four major index futures also changed, with some increasing and some decreasing [1][2][3]. 3. Summary by Relevant Catalogs 3.1 Index Futures Data Tracking - **Closing Price and Fluctuation**: The closing prices of various index futures showed different degrees of increase or decrease. For example, the CSI 300 index closed at 4734.5, up 0.05%; the SSE 50 index closed at 3075.9, down 0.12%; the CSI 500 index closed at 8288, up 0.67%; and the CSI 1000 index closed at 8265.7, up 0.40% [1]. - **Basis**: The basis of different index futures and their contracts also varied. For instance, the basis of IF2602 was -1.66, and that of IH2602 was 0.46 [1]. - **Trading Volume and Open Interest**: The trading volume and open interest of each index futures contract changed. For example, the trading volume of IF2602 decreased by 5290 lots, and the open interest decreased by 1168 lots [1]. 3.2 Market Activity - **Trading Volume**: The total trading volume of index futures decreased. Specifically, the total trading volume of IF decreased by 34310 lots, IH by 18564 lots, IC by 21181 lots, and IM by 35971 lots [2]. - **Open Interest**: The total open interest of index futures also changed. The total open interest of IF decreased by 4289 lots, IH by 1610 lots, IC increased by 6196 lots, and IM increased by 1234 lots [3]. 3.3 Top 20 Member Positions The positions of the top 20 members in different index futures contracts changed. For example, in the IF2601 contract, the long - position decreased by 1007 lots, and the short - position decreased by 724 lots [5]. 3.4 Trend Intensity The trend intensity of IF and IH is 1, and that of IC and IM is also 1. The trend intensity ranges from - 2 to 2, with - 2 being the most bearish and 2 being the most bullish [6]. 3.5 Important Drivers - **A - share Market**: A - shares were in a shrinking and volatile state. The Shanghai Composite Index rose 0.29% to 4114 points, the Shenzhen Component Index rose 0.09%, the ChiNext Index fell 0.7%, and the total trading volume of A - shares was 2.73 trillion yuan, down from 3.06 trillion yuan the previous day [7]. - **Hong Kong Stock Market**: Hong Kong stocks opened lower and closed lower. The Hang Seng Index fell 1.05% to 26563.9 points, the Hang Seng Tech Index fell 1.24%, and the total trading volume was 2256.9 billion Hong Kong dollars, down from 2550.79 billion Hong Kong dollars the previous day [7]. - **Macroeconomic Data**: In 2025, China's GDP was 1401879 billion yuan, a 5% increase compared to the previous year. The national population at the end of 2025 was 1404890000, a decrease of 3390000 from the previous year, with a natural population growth rate of - 2.41‰ [7][8].

Summary of Key Points from Conference Call Records Industry Overview - **Consumer Sector**: The consumer sector showed weakness in Q4 2026, with retail sales growth of only 0.7% year-on-year. Key categories like home appliances, furniture, and petroleum products experienced declines. Durable goods faced challenges due to subsidy exhaustion and falling real estate sales [1][3] - **Service Consumption**: Service consumption grew by 5.5% year-on-year in December 2026, benefiting from consumption upgrades and government support. The overall growth for the year is expected to reach 6.5% [1][4][5] - **E-commerce Tax Impact**: The introduction of e-commerce tax has significantly impacted the industry in the short term, leading to a decline in growth rates for platforms like Douyin and Alibaba. However, it may promote fair competition and improve the survival rate of quality brands in the long term [2][17] Company-Specific Insights - **Li Ning**: The brand's retail sales in Q4 showed a minor decline, with online sales stable and offline sales decreasing. The company is focusing on popular shopping districts and has plans for marketing initiatives around the Winter Olympics [1][8][10] - **Leisure Company (乐舒氏)**: The company is rapidly growing in emerging markets, with a projected revenue increase of 19% and a net profit growth of 127% in 2024. It has established a strong presence in Africa and is expanding into Latin America and Central Asia [1][11][12] - **TCL Electronics**: The company is expected to benefit from a strong brand presence due to major sports events in 2026. Profit margins are recovering, and the stabilization of panel prices is favorable for long-term growth [1][15] - **Hong Kong Restaurant Chains**: Recommended companies include Hai Tian International, Yi Hai International, and Wei Long, with potential for valuation recovery and growth driven by improved supply chain dynamics [1][7][24] Market Trends and Predictions - **Tool Chain Industry**: The tool chain industry is experiencing a positive trend, with inventory levels at historical lows and expectations of interest rate cuts in the US. This could lead to significant upside potential for companies like 全丰控股 [1][14] - **Travel Industry (携程)**: Despite facing antitrust investigations, the company maintains strong competitive advantages. A $5 billion share buyback plan is expected to support stock prices, and long-term valuation remains reasonable [1][19][20] Additional Insights - **Durable Goods Outlook**: The future of durable goods is uncertain, with potential improvements contingent on stabilization in the real estate market. Current growth is primarily driven by service consumption [1][6] - **Investment Opportunities**: The restaurant sector presents investment opportunities due to low valuations and attractive dividend yields. Companies like 百胜 and 海底捞 are highlighted for their potential [1][24] This summary encapsulates the key points from the conference call records, providing insights into industry trends, company performances, and market predictions.

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing significant capital inflow, indicating a potential favorable timing for investment in this sector as the innovative drug ETF (520880) shows strong performance despite recent declines [1][3][8]. Group 1: Market Performance - On January 19, the Hong Kong Stock Connect innovative drug ETF (520880) fell by 2.72%, marking three consecutive days of decline, yet recorded a net subscription of 85.51 million yuan, the highest single-day inflow in nearly a month [1][8]. - The latest fund size of the innovative drug ETF reached 2.296 billion yuan, maintaining a historical high with a total of 4.25 billion shares [4][11]. Group 2: Investment Opportunities - Short-term prospects for leading pharmaceutical companies are promising, with 2025 earnings forecasts potentially exceeding expectations, which could lead to valuation recovery opportunities [3][10]. - The first quarter is typically a peak period for overseas licensing transactions, making innovative drug companies with pipeline value, such as those with ADC, bispecific antibodies, and small RNA platforms, worthy of attention [3][10]. Group 3: Long-term Sector Logic - The core logic of the Hong Kong Stock Connect innovative drug sector remains robust, with expected overseas licensing totals for innovative drugs reaching 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][10]. - Continued policy support is anticipated, with the National Medical Products Administration (NMPA) expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the drug review and approval process [3][10]. Group 4: ETF Characteristics - The innovative drug ETF (520880) exclusively invests in innovative drug R&D companies, with over 73% of the top ten holdings representing leading firms in the sector, indicating a strong core strength [5][12][14]. - The ETF is designed to manage risks effectively by reducing the weight of less liquid component stocks, thereby controlling tail risks [6][13].

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a surge in overseas orders and mergers, indicating a vibrant market as companies engage in international collaborations and acquisitions [1][2] Group 1: International Collaborations - Since January, local companies like West Bioman and Rongchang Biopharmaceutical have completed at least five overseas licensing agreements with multinational pharmaceutical firms, showcasing active global transaction capabilities [1] - China's drug pipeline accounts for approximately 30% of the global total, ranking second worldwide, which signifies a shift from following to leading in the biopharmaceutical sector [2] - It is projected that by 2025, the total value of innovative drug licensing transactions from China will exceed $130 billion, with over 150 deals, significantly surpassing the previous year's figures [2] Group 2: Mergers and Acquisitions - China National Pharmaceutical announced a full acquisition of Hegia Biopharmaceutical for RMB 1.2 billion, aiming to enter the small interfering RNA (siRNA) innovative drug sector and expand its pipeline in cardiovascular and metabolic diseases [3] - WuXi AppTec plans to acquire Easton Pharmaceuticals at HKD 4.00 per share to enhance its capabilities in the commercial production of antibody-drug conjugates [3] - Aopu Mai has completed the acquisition of Pengli Biopharmaceutical, integrating it as a wholly-owned subsidiary to strengthen industry chain collaboration and achieve business integration [4] Group 3: Future Outlook - Companies like Fuhong Hanlin expect to launch over 20 products globally by 2030, with more than 15 anticipated to be approved in the US and Europe [5] - Jiangsu Hengrui Medicine has over 100 innovative products in clinical development and expects multiple milestone advancements in 2026, including approvals for over 10 innovative drugs or indications [5]

Fixed Income - In 2025, China's total foreign trade import and export reached 45.47 trillion yuan, a historical high, with a year-on-year growth of 3.8% [7] - The People's Bank of China announced a 0.25 percentage point reduction in various structural monetary policy tool rates starting January 19 [8] - The bond market is expected to perform better than anticipated in 2026, with a focus on potential rebounds in long-term bonds [10] - The average issuance rate for AA+ and below urban investment bonds and industrial bonds is in the range of 2.3-2.5% [13] New Consumption - In December 2025, the total retail sales of consumer goods reached 45,136 billion yuan, with a year-on-year growth of 0.9% [17] - Urban and rural retail sales in December were 38,429 billion yuan and 6,707 billion yuan, respectively, with year-on-year growth of 0.7% and 1.7% [18] - The growth rate of catering retail sales outpaced that of goods, indicating a shift in consumer spending patterns [19] Pharmaceutical Industry - The US tumor gene testing industry is accelerating, with significant opportunities in the domestic market [21] - The pharmaceutical index fell by 0.68%, with a relative underperformance compared to the CSI 300 index [22] - The report suggests focusing on innovative drug companies and medical technology sectors, highlighting companies like China Biologic Products and Shanghai Yizhong [25] - The domestic market for MRD and early tumor screening is expected to grow rapidly, mirroring trends in the US [23] Public Utilities and Environmental Protection - In 2025, China's total electricity consumption exceeded 10 trillion kWh for the first time, with the tertiary industry and urban residents contributing 50% to the growth [32] - The National Grid's investment plan for the "14th Five-Year Plan" is expected to reach 4 trillion yuan, marking the highest historical investment in the grid [35] - The report emphasizes the importance of enhancing power supply quality and the need for a robust grid to accommodate increasing electricity demand [34] Technology and Robotics - The global humanoid robot shipment is projected to reach 13,318 units in 2025, with significant contributions from Chinese manufacturers [27] - The report highlights key companies in the humanoid robot supply chain, including KAIT and Dingzhi Technology, which are making strides in product development [28] - The North Exchange technology growth stocks showed a median increase of +1.89% during the reporting period [28]

Market Overview - The Hong Kong stock market experienced a decline on January 19, with the Hang Seng Index falling by 0.76% [1] - The pharmaceutical sector faced significant losses, particularly in the innovative drug industry, with major stocks like Alibaba Health and others in the AI medical concept continuing to drop [1][10] Innovative Drug Sector Performance - The innovative drug sector saw a broad adjustment, with leading companies experiencing declines: China Biologic Products fell by 6.19%, CanSino Biologics by 3%, and others like Innovent Biologics and Hansoh Pharmaceutical dropped over 4% [1][13] - The Hong Kong Stock Connect Innovative Drug ETF (520880) fell by 2.72%, marking a three-day losing streak and losing both the 10-day and 60-day moving averages, with trading volume increasing by over 50% to 390 million HKD [11][12] Factors Influencing Market Sentiment - The adjustments in the innovative drug sector are attributed to the market digesting sentiments post the JPMorgan Healthcare Conference, which concluded on January 15, and a cautious outlook ahead of upcoming earnings forecasts for 2025 [4][15] - The market is currently in a phase of waiting for actual revenue and profit data, leading to a tendency to avoid uncertainty, particularly for companies that are not yet profitable or are in the early stages of commercialization [4][15] Future Outlook for Innovative Drug Sector - The innovative drug sector is expected to see significant earnings forecasts from leading companies in 2025, which could present opportunities for valuation recovery if results exceed expectations [5][16] - The sector's long-term fundamentals remain strong, with projections indicating that the total overseas licensing revenue for innovative drugs could reach 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [16] - Continued policy support is anticipated, with the National Medical Products Administration expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the review and approval processes [16] Investment Strategy - The Hong Kong Stock Connect Innovative Drug ETF (520880) is positioned as a high-elasticity T+0 investment tool, focusing exclusively on innovative drug R&D companies [5][16] - The ETF's index features a significant concentration of leading companies, with the top ten holdings accounting for over 73% of the total weight, indicating a strong representation of the sector's core strengths [6][17]

Market Overview - The Hong Kong stock market experienced a decline, with all three major indices dropping over 1%. The Hang Seng Index fell by 1.05% to 26,563.9 points, with a total trading volume of 225.69 billion HKD [1] - Huatai Securities noted that the core factors driving the market rebound in the first quarter remain unchanged, including overall loose financial conditions and improved profit expectations, suggesting continued opportunities for investment in Hong Kong stocks [1] Blue-Chip Stocks Performance - Li Ning (02331) reached a new high, closing up 2.94% at 21 HKD, contributing 2.21 points to the Hang Seng Index. Morgan Stanley forecasts moderate revenue growth for Li Ning by 2025, with net profit margins stabilizing at high single digits [2] - Other blue-chip stocks included Sinopec (00386) up 3.34% and Mengniu Dairy (02319) up 2.78%, while China Biologic Products (01177) fell 6.19% and Innovent Biologics (01801) dropped 4.64%, negatively impacting the index [2] Sector Highlights Aviation Stocks - Aviation stocks performed well, with China Eastern Airlines (00670) up 9.2%, China Southern Airlines (01055) up 6.29%, and Air China (00753) up 3.76%. The 2026 Spring Festival travel period is expected to see a passenger volume of 95 million, a 5.3% increase year-on-year [3] Power Equipment Stocks - Power equipment stocks rose, with Dongfang Electric (01072) up 6.38% and Harbin Electric (01133) up 5.46%. The National Energy Administration announced that China's electricity consumption is projected to exceed 10 trillion kWh by 2025, a 5% year-on-year increase [4] Gold Stocks - Gold stocks were active, with Zhaojin Mining (01818) up 3.62% and Zijin Mining (02259) up 2.47%. The international gold price surged to a historical high of 4,690 USD per ounce due to rising market risk aversion stemming from escalating US-EU tariff disputes [5] Earnings Forecasts - Companies with positive earnings forecasts saw strong performance, including Qutoutiao (00917) up 38.78% and TCL Electronics (01070) up 13.4%. Qutoutiao expects to turn a profit with a net income between 270 million to 330 million RMB for the fiscal year ending December 31, 2025 [6] Notable Stock Movements - New World Development (00017) surged 16.28% to 11.07 HKD, reaching a two-year high, as the company’s chairman expressed confidence in creating value through strategic investments [7] - UBTECH Robotics (09880) rose 8.63% after signing a service agreement with Airbus for humanoid robots [8] - China National Offshore Oil Corporation (01138) climbed 7.39% amid favorable conditions in the oil transportation market due to geopolitical changes [9] - China Duty Free Group (01880) increased by 6.65% following strong growth in duty-free shopping in Hainan [10] - Cambridge Technology (06166) fell 12.2% after reporting lower-than-expected fourth-quarter profits despite a projected annual profit increase [11]

Market Overview - The Hong Kong stock market experienced a decline, with all three major indices dropping over 1%. The Hang Seng Index closed down 1.05% at 26,563.9 points, with a total trading volume of HKD 2,256.89 million [1] - The Hang Seng China Enterprises Index fell 0.94% to 9,134.45 points, while the Hang Seng Tech Index decreased by 1.24% to 5,749.98 points [1] Blue-Chip Stocks Performance - Li Ning (02331) reached a new high, closing up 2.94% at HKD 21, contributing 2.21 points to the Hang Seng Index. Morgan Stanley forecasts moderate revenue growth for Li Ning by 2025, with net profit margins stabilizing at high single digits [2] - Other blue-chip stocks included Sinopec (00386) up 3.34% at HKD 4.95, and Mengniu Dairy (02319) up 2.78% at HKD 15.89. China Biologic Products (01177) fell 6.19% to HKD 6.52, negatively impacting the index [2] Sector Highlights - The aviation sector showed strong performance, with China Eastern Airlines (00670) rising 9.2% to HKD 5.7, and China Southern Airlines (01055) increasing 6.29% to HKD 5.91 [3] - Electric power equipment stocks also gained, with Dongfang Electric (01072) up 6.38% at HKD 27.66 [4] - Gold stocks were active due to rising market risk aversion, with Zhaojin Mining (01818) increasing 3.62% to HKD 37.82 [5] Earnings Forecasts - Companies with positive earnings forecasts included Qutoutiao (00917), which surged 38.78% to HKD 35, and TCL Electronics (01070), which rose 13.4% to HKD 11.17. TCL expects a net profit growth of 45% to 60% for 2025 [6] - China Taiping (00966) anticipates a profit increase of 215% to 225% for the fiscal year ending December 31, 2025 [6] Notable Stock Movements - New World Development (00017) surged 16.28% to HKD 11.07, reaching a two-year high, driven by positive market sentiment [7] - UBTECH (09880) rose 8.63% to HKD 144.7 after signing a service agreement with Airbus for humanoid robots [8] - China International Marine Containers (01138) climbed 7.39% to HKD 12.94, supported by changes in global oil trade dynamics [9] - China Duty Free Group (01880) increased 6.65% to HKD 87.4, benefiting from strong growth in duty-free shopping in Hainan [10] - Cambridge Technology (06166) fell 12.2% to HKD 82.05, as its Q4 net profit forecast was below market expectations [11]

1月19日，香港恒生指数收跌1.05%，恒生科技指数跌1.24%。 | 科网股普跌，哔哩哔哩大跌近7%，华虹半导体、阿里健康、阿里巴巴均跌超3%，中芯国际、商汤、快手均下跌。 | | --- | | 德琪医药-B | 3.800 | -6.40% | | --- | --- | --- | | 6996.HK | | | | 华花生物-B | 10.940 | -6.34% | | 2396.HK | | | | 思路迪医药股份 | 5.510 | -6.29% | | 1244.HK | | | | 中国生物制药 | 6.520 | -6.19% | | 1177.HK | | | | 加科思-B | 6.940 | -6.09% | | 1167.HK | | | | 维亚生物 | 1.940 | -5.83% | | 1873.HK | | | | 轩竹生物-B | 66.600 | -5.73% | | 2575.HK | | | | 英矽智能 | 52.050 | -5.71% | | 2406 HK | | | 多只AI应用概念股大跌，MINIMAX跌超13%，智谱跌超10%，美图公司跌超7%。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]